| 产品描述: | p110δ 选择性抑制剂;p110δ Selective Inhibitors;;InformationNemiralisib, also known as GSK-2269557, is a potent and selectivePI3Kδinhibitor(pKi = 9.9).TargetsPI3Kδ (Cell-free assay) 9.9(pKi)In vivoGSK-2269557 has low oral bioavailability (F=2%) and in vivo clearance of 28 mL/min/kg but has a high volume of distribution of 6.3 L/kg. GSK-2269557 induces concentration-dependent increases in QT interval and Tp-e at 0.3 and 1 μM (1 and 0.5 Hz) and an increase in QRS at 1 μM (2 Hz), however, no treatment-related torsades de pointes (TdP) arrhythmias are observed. In a disease relevant brown Norway rat acute OVA model of Th2 driven lung inflammation, GSK-2269557 is shown to protect against eosinophil recruitment with an ED50 of 67 μg/kg and dose-dependently reduces recruitment of all leukocyte subpopulations and IL-13 in the lungs. |